🏅 FDA Orphan Designation
SAJAZIR
ICATIBANT
Manufacturer: Cycle Pharmaceuticals Ltd-Uk
Indicated for:
FDA-Approved Indications (1)
indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older
Population: adults 18 years of age and older
Indications & Usage
1 INDICATIONS AND USAGE SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
💙 Support Programs
View all →SAJAZIR
Cycle Pharmaceuticals Ltd-Uk
SAJAZIR
Cycle
ICATIBANT
Bryant Ranch Prepack
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.